Knockdown of long non-coding RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis

References

• Siegel RL, et al. Cancer statistics, 2021. Ca-a Cancer Journal for Clinicians. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Loibl S, Poortmans P, Morrow M. Breast cancer (vol 397, pg 1750, 2021). Lancet. 2021;397(10286): 1710-1710.
   PubMed Web of Science ®Google Scholar
• Husseini A, Abu-Rmeileh NME, Mikki N. Cardiovascular disease, diabetes mellitus, and cancer in the occupied Palestinian territory. (vol 373, pg 1041, 2009). Lancet. 2009;373(9677): 1764-1764.
   PubMed Web of Science ®Google Scholar
• Collignon J, et al. Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al reply. Breast Cancer-Targets and Therapy. 2016;8: 159-159.
   PubMed Web of Science ®Google Scholar
• Carey LA, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. Jama-Journal of the American Medical Association. 2006;295(21):2492–2502.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, et al. NCCN guidelines (R) insights breast cancer, version 1.2017 featured updates to the NCCN guidelines. J National Compr Cancer Network. 2017;15(4):433-+.
   Web of Science ®Google Scholar
• Jatoi I, Kemp Z. Surgery for breast cancer prevention. Jama-Journal of the American Medical Association. 2021;325(17): 1804-1804. DOI:10.1001/jama.2021.1647
   Web of Science ®Google Scholar
• Liu SJ, et al. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021;21(7):446–460.
   PubMed Web of Science ®Google Scholar
• Statello L, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118.
   PubMed Web of Science ®Google Scholar
• Ma JY, et al. Metabolism-related long non-coding RNAs (lncRNAs) as potential biomarkers for predicting risk of recurrence in breast cancer patients. Bioengineered. 2021;12(1):3726–3736.
   PubMed Web of Science ®Google Scholar
• Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nat Cell Biol. 2019;21(5):542–551.
   PubMed Web of Science ®Google Scholar
• Ning ML, et al. LncRNA AFAP-AS1 promotes anaplastic thyroid cancer progression by sponging miR-155-5p through ETS1/ERK pathway. Bioengineered. 2021;12(1):1543–1554.
   PubMed Web of Science ®Google Scholar
• Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–352.
   PubMed Web of Science ®Google Scholar
• Volovat SR, et al. MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: a review. Front Oncol. 2020;10. DOI:10.3389/fonc.2020.526850
   PubMed Web of Science ®Google Scholar
• Lv YF, et al. LncRNA SNHG6/miR-125b-5p/BMPR1B axis: a new therapeutic target for triple-negative breast cancer. Front Oncol. 2021;11. DOI:10.3389/fonc.2021.678474
   Web of Science ®Google Scholar
• Xie XN, et al. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription. Cell Death Dis. 2021;12(2.
   Web of Science ®Google Scholar
• Huang K, et al. Effects of CDKN2B-AS1 polymorphisms on the susceptibility to coronary heart disease. Mol Genet Genomic Med. 2019;7(11.
   Web of Science ®Google Scholar
• Timmers PRHJ, et al. Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances. Elife. 2019;8.
   PubMed Web of Science ®Google Scholar
• Toraih EA, et al. Deciphering the role of circulating lncRNAs: RNCR2, NEAT2, CDKN2B-AS1, and PVT1 and the possible prediction of anti-VEGF treatment outcomes in diabetic retinopathy patients. Graefes Archive for Clinical and Experimental Ophthalmology. 2019;257(9):1897–1913.
   PubMed Web of Science ®Google Scholar
• Luo ZB, et al. A competing endogenous RNA network reveals novel lncRNA, miRNA and mRNA biomarkers with diagnostic and prognostic value for early breast cancer. Technol Cancer Res Treat. 2020;19:153303382098329.
   Web of Science ®Google Scholar
• Song CY, et al. CDKN2B-AS1: An indispensable long non-coding RNA in multiple diseases. Curr Pharm Des. 2020;26(41):5335–5346.
   PubMed Web of Science ®Google Scholar
• Kattan SW, et al. Association of cyclin-dependent kinase inhibitor 2B antisense RNA 1 gene expression and rs2383207 variant with breast cancer risk and survival. Cell Mol Biol Lett. 2021;26(1.
   Web of Science ®Google Scholar
• Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21(1):22–36.
   PubMed Web of Science ®Google Scholar
• Chuffa LGD, et al. A meta-analysis of microRNA networks regulated by melatonin in cancer: portrait of potential candidates for breast cancer treatment. J Pineal Res. 2020;69(4.
   Web of Science ®Google Scholar
• Fabris L, et al. The potential of MicroRNAs as prostate cancer biomarkers. Eur Urol. 2016;70(2):312–322.
   PubMed Web of Science ®Google Scholar
• Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149(5):1177-+.
   Web of Science ®Google Scholar
• Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143(1):35–U543.
   PubMed Web of Science ®Google Scholar
• Pu MF, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019;76(3):441–451.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003;100(17):9779–9784.
   PubMed Web of Science ®Google Scholar
• Liang YJ, et al. lncRNA-SOX2OT promotes hepatocellular carcinoma invasion and metastasis through miR-122-5p-mediated activation of PKM2. Oncogenesis. 2020;9(5.
   Web of Science ®Google Scholar
• Gao L, et al. Up-regulation of FSTL3, regulated by lncRNA DSCAM-AS1/miR-122-5p axis, promotes proliferation and migration of non-small cell lung cancer cells. Onco Targets Ther. 2020;13:2725–2738.
   PubMed Web of Science ®Google Scholar
• Ma WG, et al. The LINC01410/miR-122-5p/NDRG3 axis is involved in the proliferation and migration of osteosarcoma cells. Iubmb Life. 2021;73(4):705–717.
   PubMed Web of Science ®Google Scholar
• Zhang W, et al. Resveratrol chemosensitizes adriamycin-resistant breast cancer cells by modulating miR-122-5p. J Cell Biochem. 2019;120(9):16283–16292.
   PubMed Web of Science ®Google Scholar
• Zhang CF, et al. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway. Theranostics. 2021;11(5):2108–2122.
   PubMed Web of Science ®Google Scholar
• Huang T, et al. STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation. Oncol Lett. 2017;14(4):4599–4604.
   PubMed Web of Science ®Google Scholar
• Shen CH, et al. SPAK-p38 MAPK signal pathway modulates claudin-18 and barrier function of alveolar epithelium after hyperoxic exposure. BMC Pulm Med. 2021;21(1.
   Web of Science ®Google Scholar
• Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–549.
   PubMed Web of Science ®Google Scholar
• Wen SY, et al. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin beta 3-p38 MAPK signalling. Cancer Lett. 2019;442:320–332.
   PubMed Web of Science ®Google Scholar
• Li CX, et al. MicroRNA-299-5p inhibits cell metastasis in breast cancer by directly targeting serine/threonine kinase 39. Oncol Rep. 2020;43(4):1221–1233.
   PubMed Web of Science ®Google Scholar
• Wang GL, Xu GH, Wang WG. Long noncoding RNA CDKN2B-AS1 facilitates lung cancer development through regulating miR-378b/NR2C2. Onco Targets Ther. 2020;13:10641–10649.
   PubMed Web of Science ®Google Scholar
• Dasgupta P, et al. LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma. Cell Death Dis. 2020;11(8.
   Web of Science ®Google Scholar
• Cai YX, et al. Low-coverage sequencing of urine sediment DNA for detection of copy number aberrations in bladder cancer. Cancer Manag Res. 2021;13:1943–1953.
   PubMed Web of Science ®Google Scholar
• Abula A, et al. The stimulative function of long noncoding RNA CDKN2B-AS1 in osteosarcoma by targeting the microRNA-122/CCNG1 axis. J Recept Signal Transduct. 2020;1–9. doi:10.1080/10799893.2020.1850784
   PubMed Web of Science ®Google Scholar
• Li Z, et al. Role of high expression levels of STK39 in the growth, migration and invasion of non-small cell type lung cancer cells. Oncotarget. 2016;7(38):61366–61377.
   PubMedGoogle Scholar
• Shen XY, et al. LncRNA CDKN2B-AS1 promotes cell viability, migration, and invasion of hepatocellular carcinoma via sponging miR-424-5p. Cancer Manag Res. 2020;12:6807–6819.
   PubMed Web of Science ®Google Scholar